Skip to main
COGT

COGT Stock Forecast & Price Target

COGT Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. With a promising pipeline of targeted oncology treatments, including the potential launch of its flagship drug bezuclastinib for multiple indications, the company is well-positioned in the market. Despite potential risks such as clinical trial setbacks and competition, Cogent's strong financials, with a projected cash runway into 2028, make it a compelling investment opportunity.

Bears say

Cogent Biosciences is facing hurdles in obtaining regulatory approvals for its precision therapies due to potential negative clinical data, slower development timelines, and setbacks in later-stage trials. Additionally, there is a risk of failure to obtain regulatory approvals and setbacks with its earlier-stage candidates, which could hinder the company's commercial success and lead to long-term dilution risk for investors. As a result, there is a negative outlook on the company's stock.

COGT has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogent Biosciences, Inc. (COGT) Forecast

Analysts have given COGT a Buy based on their latest research and market trends.

According to 9 analysts, COGT has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogent Biosciences, Inc. (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.